Trial: 201910200

Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma

Phase

II

Principal Investigator

Schroeder, Mark

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov